April 18, 2025

Global Study Validates Melanoma Risk Tool

An international study of 15,731 patients found the MIA sentinel node calculator maintains accuracy across populations and now offers tighter confidence intervals after model refinement.

Conexiant

April 17, 2025

Climate Identified as Key Virus Driver

Researchers found Oropouche virus to be underreported during a large-scale study across Latin America, with climate emerging as the primary driver of transmission risk.

Conexiant

April 08, 2025

Season of Conception May Impact BMI

Preconception cold exposure may enhance brown fat activity and metabolic health.

Conexiant

March 31, 2025

Sex Matters: Key Finding in Alzheimer's Disease Progression

"Sex differences in the pathological progression of AD call for sex-specific timing considerations when administrating anti-Aβ and anti-tau treatments."

Conexiant

February 10, 2025

Study Probes Depression-Amyloid Link in Aging

Study finds depressive symptoms in older adults were not consistently tied to amyloid pathology, but were linked to lower amyloid levels in MCI.

Conexiant

November 07, 2024

AI in Neuropathology: How Language Models Are Transforming Brain Tumor Diagnosis

New research explores how integrating AI with clinical guidelines can enhance diagnostic precision for complex brain tumors.

Conexiant

November 18, 2024

The Adaptive Immune System's Role in Gut Health and IBD

Researchers identified segment-specific effects of immune cells on intestinal contractions, providing new angles for managing inflammatory bowel disease.

Conexiant

March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant

February 04, 2025

Predicting Response to KRAS G12C Inhibitors in NSCLC

Investigators discovered that measuring the interaction between the RAS and RAF proteins could provide valuable insights into the effectiveness of treatments in patients with KRAS G12C–mutated NSCLC.

The ASCO Post